The Vanguard Group 13D and 13G filings for Cytokinetics, Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-08 11:29 am Purchase | 2024-12-31 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 11,915,821 10.090% | 154,216 (+1.31%) | Filing |
| 2024-11-12 2:21 pm Unchanged | 2024-09-30 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 11,761,605 9.990% | 0 (Unchanged) | Filing |
| 2024-11-04 11:17 am Purchase | 2024-09-30 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 11,761,605 9.990% | 744,716 (+6.76%) | Filing |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 11,016,889 11.240% | 943,795 (+9.37%) | Filing |
| 2023-02-09 11:16 am Purchase | 2022-12-30 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 10,073,094 10.640% | 1,331,970 (+15.24%) | Filing |
| 2022-04-08 4:31 pm Purchase | 2022-03-31 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 8,741,124 10.300% | 1,751,405 (+25.06%) | Filing |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 6,989,719 8.330% | 2,167,729 (+44.96%) | Filing |
| 2021-02-10 10:46 am Purchase | 2020-12-31 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 4,821,990 6.810% | 276,000 (+6.07%) | Filing |
| 2020-02-12 11:01 am Purchase | 2019-12-31 | 13G | Cytokinetics, Incorporated CYTK | The Vanguard Group | 4,545,990 7.680% | 944,078 (+26.21%) | Filing |